Analysts expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report $1.13 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for IDEXX Laboratories’ earnings. The lowest EPS estimate is $1.12 and the highest is $1.14. IDEXX Laboratories posted earnings per share of $1.05 in the same quarter last year, which would indicate a positive year-over-year growth rate of 7.6%. The business is scheduled to announce its next quarterly earnings report on Thursday, November 7th.

According to Zacks, analysts expect that IDEXX Laboratories will report full-year earnings of $4.86 per share for the current fiscal year, with EPS estimates ranging from $4.84 to $4.88. For the next financial year, analysts anticipate that the company will report earnings of $5.57 per share, with EPS estimates ranging from $5.44 to $5.65. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover IDEXX Laboratories.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $1.43 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.37 by $0.06. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The business had revenue of $620.10 million for the quarter, compared to analyst estimates of $627.10 million. During the same period in the prior year, the business posted $1.23 earnings per share. IDEXX Laboratories’s revenue was up 6.8% compared to the same quarter last year.

Several equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 price objective on the stock in a report on Friday, May 3rd. Bank of America set a $300.00 price objective on shares of IDEXX Laboratories and gave the company a “buy” rating in a report on Friday, June 21st. Canaccord Genuity restated a “buy” rating and issued a $285.00 price objective on shares of IDEXX Laboratories in a report on Friday, August 2nd. BidaskClub lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Friday, July 26th. Finally, Stifel Nicolaus increased their target price on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the stock a “buy” rating in a report on Monday, July 22nd. Seven investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $286.67.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 20,000 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.26, for a total value of $5,245,200.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Rebecca M. Henderson sold 4,000 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $271.17, for a total transaction of $1,084,680.00. Following the completion of the sale, the director now owns 14,696 shares in the company, valued at $3,985,114.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 75,905 shares of company stock worth $20,052,806. Company insiders own 2.70% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Chicago Capital LLC raised its holdings in shares of IDEXX Laboratories by 1.1% during the second quarter. Chicago Capital LLC now owns 113,341 shares of the company’s stock worth $31,206,000 after acquiring an additional 1,240 shares during the period. HCR Wealth Advisors acquired a new stake in shares of IDEXX Laboratories during the second quarter worth $218,000. WINTON GROUP Ltd raised its holdings in shares of IDEXX Laboratories by 20.5% during the second quarter. WINTON GROUP Ltd now owns 5,010 shares of the company’s stock worth $1,379,000 after acquiring an additional 852 shares during the period. Piedmont Investment Advisors Inc. raised its holdings in shares of IDEXX Laboratories by 1.9% during the first quarter. Piedmont Investment Advisors Inc. now owns 7,633 shares of the company’s stock worth $1,707,000 after acquiring an additional 144 shares during the period. Finally, Swiss National Bank raised its holdings in shares of IDEXX Laboratories by 2.2% during the first quarter. Swiss National Bank now owns 287,800 shares of the company’s stock worth $64,352,000 after acquiring an additional 6,100 shares during the period. Institutional investors own 87.10% of the company’s stock.

NASDAQ IDXX traded up $0.25 during trading hours on Friday, hitting $281.66. The company’s stock had a trading volume of 6,345 shares, compared to its average volume of 414,739. The stock has a fifty day moving average of $279.43 and a 200 day moving average of $244.86. IDEXX Laboratories has a twelve month low of $176.11 and a twelve month high of $292.17. The firm has a market capitalization of $23.71 billion, a P/E ratio of 66.09 and a beta of 0.84. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 4.49.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Featured Article: Why is the ex-dividend date different from the record date?

Get a free copy of the Zacks research report on IDEXX Laboratories (IDXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.